NCT06979518View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

November 25, 2025

Study Completion Date

April 27, 2026

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GSK3862995B

GSK3862995B will be administered.

DRUG

Placebo

Matching placebo will be administered.

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06979518 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry | Biotech Hunter | Biotech Hunter